

TO: Interested Parties


FR: Morning Consult

DT: July 2026

RE: Medicaid Coverage of FDA-Approved Obesity Medicines

Morning Consult conducted a survey on behalf of the Chronic Care Policy Alliance among 2,001 registered voters across the United States. Voters across party lines overwhelmingly view obesity as a serious chronic disease that deserves medical treatment, strongly support efforts to help eligible patients access FDA-approved obesity medicines, and believe Medicaid should play a role in providing coverage. These attitudes translate into a meaningful political upside, with voters rewarding policymakers who support expanding access to obesity treatment.

Obesity is a Serious Problem




% Total problem (Very + Somewhat)

Obesity is a Major Public Health Concern

- The vast majority of U.S. voters (71%) see obesity as a serious problem in their state, with over one-quarter saying it is a *very serious issue*, and a majority (56%) reporting a personal connection to obesity.
- Four-in-five U.S. voters (82%) agree obesity deserves the same coverage as other chronic diseases, with nearly half strongly agreeing (46%).

Obesity is a Chronic Disease That Deserves Equal Coverage as Other Chronic Diseases




% Total agree (Strongly + Somewhat)

Voters Want Patients to Have Access to Treatment

- Most voters agree all residents, regardless of income or socioeconomic status, should have **equal access to obesity medicines** (80%) and believe **doctors should drive decision-making** (78%).
- Four-in-five U.S. voters (78%) are **deeply concerned that some patients are unable to access FDA-approved obesity treatments** their doctors recommend because their state Medicaid program does not cover them.
- While only 19% are *very familiar* with obesity medicines, nearly three-in-five voters (56%) **view obesity as a chronic disease that should be treated with obesity medicines** – not simply a matter of personal and lifestyle changes (44%).
- U.S. voters reject cost-based arguments against coverage. More than half (56%) believe Medicaid coverage for obesity medicines is **an investment in long-term health** that prevents costly complications and reduces healthcare costs, rather than viewing medicines as too expensive for Medicaid to cover (26%).

All Residents Should Have Equal Access To Obesity Medicines



% Total agree (Strongly + Somewhat)



- Underscoring the importance of access, four-in-five voters in the U.S. (79%) recognize the **importance of obesity treatment for communities that face higher rates of chronic diseases** and agree that Medicaid **coverage of obesity medicines would help improve lives** and lead to better health outcomes (78%).

U.S. Voter Sentiment on Obesity Medicines


% Total Agree (Strongly + Somewhat)



Medicaid Has a Responsibility to Help Provide Access

- Most U.S. voters (80%) think it is **important for policymakers to provide access** to obesity medicines in their state.
- Most U.S. voters also **support policies that would broaden access for low-income patients** – including **establishing a program in their state** (78%) or **expanding Medicaid eligibility** (76%) – to ensure they have access to obesity medications.
- The majority of U.S. voters (76%) support **their state's Medicaid program providing** FDA-approved obesity treatments for eligible patients.
 - Support for state Medicaid coverage of obesity treatments is strong across party, with majorities of Democrats (82%), Independents (70%), and Republicans (75%) in the U.S. backing this coverage.

More Likely to Support Politicians Backing Medicaid Coverage



% More likely to support
(Much more + Somewhat more)

U.S. Voters Reward Policymakers Who Support Medicaid Coverage of Obesity Medicines

- 70% of U.S. voters say they are **more likely to support legislators who back Medicaid providing obesity medicine coverage**, versus just 13% who say less likely.
 - Democrats (81%), Independents (64%), and Republicans (64%) in the U.S. are more likely to support lawmakers who back Medicaid coverage of FDA-approved obesity medications.